LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance
Molecular & Cellular Proteomics · 2026
DOI: 10.1016/j.mcpro.2026.101514 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026. Verfasst von Owen F J Hovey und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Imatinib Mesylate, Drug Resistance, Neoplasm, RNA-Binding Proteins, Proteome. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Ontario Ministry of Research and Innovation.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) resistance to BCR-ABL tyrosine kinase inhibitors can arise from ABL kinase domain mutations, BCR-ABL fusion gene amplification, or kinase-independent mechanisms. To investigate imatinib-resistance, we performed quantitative mass spectrometry comparing the proteome and phosphoproteome of K562 cells (a standard CML model) and ImR cells, an imatinib-resistant K562 derivative that also exhibits cross-resistance to second- and third-generation BCR-ABL tyrosine kinase inhibitors. In addition to revealing global proteome and phosphoproteome changes associated with drug resistance, we identified LIN28A-a multifunctional RNA-binding protein-as a critical mediator of imatinib resistance. LIN28A was significantly overexpressed and hyperphosphorylated in ImR cells. Depleting LIN28A via shRNA restored imatinib sensitivity, while its ectopic expression in parental K562 cells induced imatinib resistance. Mechanistically, LIN28A coordinates an extensive kinase-substrate network regulating proliferation, survival, and metabolism to drive resistance. Notably, pharmacological inhibition of LIN28A-dependent kinases (PKC, AKT, SGK1, and RPS6K) suppressed ImR proliferation. Midostaurin, a clinical PKC/FLT3 inhibitor used in FLT3-ITD-positive AML, potently resensitized ImR cells to imatinib. Our findings suggest that targeting LIN28A and its downstream effectors, particularly PKC, could overcome resistance to imatinib and next-generation BCR-ABL inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Western University, London, Ontario, Canada.
- Department of Biochemistry, Western University, London, Ontario, Canada. Electronic address: ilka.heinemann@uwo.ca.
- Department of Biochemistry, Western University, London, Ontario, Canada; Department of Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Electronic address: sli@uwo.ca.
Förderung
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Ontario Ministry of Research and Innovation
Zitieren
APA
Hovey, O. F. J., Frederick, M. I., Quach, Q. M., Kakadia, J. H., Wu, A., Yang, K., Wu, T., Ruan, X., Kaneko, T., Voss, C., Heinemann, I. U., & Li, S. S. C. (2026). LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance. Molecular & Cellular Proteomics. https://doi.org/10.1016/j.mcpro.2026.101514
Vancouver
Hovey OFJ, Frederick MI, Quach QM, Kakadia JH, Wu A, Yang K, et al. LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance. Molecular & Cellular Proteomics. 2026. doi:10.1016/j.mcpro.2026.101514
BibTeX
@article{Hovey2026,
author = {Hovey, Owen F J and Frederick, Mallory I and Quach, Quan M and Kakadia, Jenica H and Wu, Alyssa and Yang, Kyle and Wu, Tingting and Ruan, Xiang and Kaneko, Tomonori and Voss, Courtney and Heinemann, Ilka U and Li, Shawn S C},
title = {LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance},
journal = {Molecular & Cellular Proteomics},
year = {2026},
doi = {10.1016/j.mcpro.2026.101514}
}
EUVIMED